About AAVANTIBio
AAVANTIBio is a company based in Gainesville (United States) founded in 2017 was acquired by Solid Biosciences in September 2022. AAVANTIBio has raised $107 million across 1 funding round from investors including Solid Biosciences, Sarepta Therapeutics and Bain Capital. AAVANTIBio operates in a competitive market with competitors including Jazz Pharmaceuticals, Senti Biosciences, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Gainesville, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$107 M (USD)
in 1 rounds
-
Latest Funding Round
$107 M (USD), Series A
Oct 22, 2020
-
Investors
Solid Biosciences
& 4 more
-
Employee Count
Not available
-
Acquired by
Solid Biosciences
(Sep 30, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of AAVANTIBio
Unlock access to complete
Unlock access to complete
Funding Insights of AAVANTIBio
AAVANTIBio has successfully raised a total of $107M through 1 strategic funding round. The most recent funding activity was a Series A round of $107 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AAVANTIBio
AAVANTIBio has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Solid Biosciences, Sarepta Therapeutics and Bain Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Debt and equity investments are pursued across multiple sectors.
|
Locked | Locked | Locked | |
|
RA Capital is engaged in evidence-based investing in healthcare and life sciences.
|
Locked | Locked | Locked |
Investor details for AAVANTIBio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AAVANTIBio
Investment portfolio details for AAVANTIBio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AAVANTIBio
Detailed financials for AAVANTIBio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aavantibio Comparisons
Peer comparison for AAVANTIBio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AAVANTIBio
AAVANTIBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Senti Biosciences, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Cell-based therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
Detailed competitors of AAVANTIBio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aavantibio
Complete news archive for AAVANTIBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AAVANTIBio
AAVANTIBio was founded in 2017 and raised its 1st funding round 3 years after it was founded.
AAVANTIBio is headquartered in Gainesville, United States.
AAVANTIBio is a funded company, having raised a total of $107M across 1 funding round to date.
AAVANTIBio was founded in 2017 and is based in Gainesville, United States. Focus is placed on biotechnology within the gene therapy sector. Gene-editing technologies are developed to target fatal neuromuscular conditions. Operations center on AAV-mediated gene transfer approaches, with the lead program directed at Friedreichs ataxia. Research and development activities aim to address unmet needs in disease treatment through innovative delivery methods.
AAVANTIBio's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
AAVANTIBio has 5 investors. Key investors include Solid Biosciences, Sarepta Therapeutics, Bain Capital, RA Capital, and Perceptive Advisors.